{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T22:43:31Z","timestamp":1790808211460,"version":"4.1.0"},"reference-count":68,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,6,28]],"date-time":"2021-06-28T00:00:00Z","timestamp":1624838400000},"content-version":"am","delay-in-days":331,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100001677","name":"Institut National de la Sant\u00c3\u00a9 et de la Recherche M\u00c3\u00a9dicale","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001677","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007525","name":"Universit\u00c3\u00a9 de Rennes 1","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007525","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical Pharmacology"],"published-print":{"date-parts":[[2020,8]]},"DOI":"10.1016\/j.bcp.2020.114103","type":"journal-article","created":{"date-parts":[[2020,6,17]],"date-time":"2020-06-17T11:21:03Z","timestamp":1592392863000},"page":"114103","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":155,"special_numbering":"C","title":["Combined anti-fibrotic and anti-inflammatory properties of JAK-inhibitors on macrophages in vitro and in vivo: Perspectives for scleroderma-associated interstitial lung disease"],"prefix":"10.1016","volume":"178","author":[{"given":"Alain","family":"Lescoat","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Lelong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed","family":"Jeljeli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Piquet-Pellorce","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudie","family":"Morzadec","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice","family":"Ballerie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e9phane","family":"Jouneau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Jego","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Vernhet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fr\u00e9deric","family":"Batteux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Fardel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Val\u00e9rie","family":"Lecureur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.bcp.2020.114103_b0005","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.4049\/jimmunol.1901477","article-title":"Translating JAKs to Jakinibs","volume":"204","author":"Gadina","year":"2020","journal-title":"J Immunol."},{"issue":"Suppl 1","key":"10.1016\/j.bcp.2020.114103_b0010","doi-asserted-by":"crossref","first-page":"i4","DOI":"10.1093\/rheumatology\/key432","article-title":"Janus kinases to jakinibs: from basic insights to clinical practice","volume":"58","author":"Gadina","year":"2019","journal-title":"Rheumatology (Oxford)."},{"issue":"12","key":"10.1016\/j.bcp.2020.114103_b0015","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1056\/NEJMoa1002028","article-title":"Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis","volume":"363","author":"Verstovsek","year":"2010","journal-title":"N Engl J Med."},{"issue":"7","key":"10.1016\/j.bcp.2020.114103_b0020","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1056\/NEJMoa1608345","article-title":"Baricitinib versus Placebo or Adalimumab in Rheumatoid Arthritis","volume":"376","author":"Taylor","year":"2017","journal-title":"N Engl J Med."},{"issue":"6","key":"10.1016\/j.bcp.2020.114103_b0025","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1056\/NEJMoa1109071","article-title":"Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis","volume":"367","author":"Fleischmann","year":"2012","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.bcp.2020.114103_b0030","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/1476-9255-7-41","article-title":"Anti-inflammatory activity and neutrophil reductions mediated by the JAK1\/JAK3 inhibitor, CP-690,550, in rat adjuvant-induced arthritis","volume":"11","author":"Meyer","year":"2010","journal-title":"J Inflamm (Lond)."},{"issue":"2","key":"10.1016\/j.bcp.2020.114103_b0035","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1136\/annrheumdis-2014-206478","article-title":"Safety and efficacy of baricitinib at 24 weeks in patients with rheumatoid arthritis who have had an inadequate response to methotrexate","volume":"74","author":"Keystone","year":"2015","journal-title":"Ann Rheum Dis."},{"issue":"6","key":"10.1016\/j.bcp.2020.114103_b0040","first-page":"4883","article-title":"The JAK inhibitor tofacitinib ameliorates immune\u2013mediated liver injury in mice","volume":"20","author":"Wang","year":"2019","journal-title":"Mol Med Rep."},{"issue":"8","key":"10.1016\/j.bcp.2020.114103_b0045","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1136\/annrheumdis-2016-210911","article-title":"JAK1-dependent transphosphorylation of JAK2 limits the anti-fibrotic effects of selective JAK2 inhibitors on long-term treatment","volume":"76","author":"Zhang","year":"2017","journal-title":"Ann Rheum Dis."},{"issue":"10","key":"10.1016\/j.bcp.2020.114103_b0050","doi-asserted-by":"crossref","first-page":"9","DOI":"10.2147\/JEP.S150729","article-title":"Pilot study of the anti-fibrotic effects of the multikinase inhibitor pacritinib in a mouse model of liver fibrosis","volume":"9","author":"Al-Fayoumi","year":"2018","journal-title":"J Exp Pharmacol."},{"issue":"10","key":"10.1016\/j.bcp.2020.114103_b0055","doi-asserted-by":"crossref","DOI":"10.1242\/jcs.209932","article-title":"RNAi screening identifies a mechanosensitive ROCK-JAK2-STAT3 network central to myofibroblast activation","volume":"15131","author":"Oh","year":"2018","journal-title":"J Cell Sci"},{"key":"10.1016\/j.bcp.2020.114103_b0060","doi-asserted-by":"crossref","DOI":"10.1007\/s12016-020-08786-6","article-title":"JAK Inhibitors: Prospects in Connective Tissue Diseases","author":"You","year":"2020","journal-title":"Clin Rev Allergy Immunol"},{"issue":"10139","key":"10.1016\/j.bcp.2020.114103_b0065","doi-asserted-by":"crossref","first-page":"2477","DOI":"10.1016\/S0140-6736(18)31325-4","article-title":"New-generation JAK inhibitors: how selective can they be?","volume":"391","author":"Goll","year":"2018","journal-title":"Lancet."},{"key":"10.1016\/j.bcp.2020.114103_b0070","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/j.intimp.2017.11.032","article-title":"Repression of interferon \u03b2-regulated cytokines by the JAK1\/2 inhibitor ruxolitinib in inflammatory human macrophages","volume":"54","author":"Febvre-James","year":"2018","journal-title":"Int Immunopharmacol."},{"issue":"11","key":"10.1016\/j.bcp.2020.114103_b0075","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1038\/nri3073","article-title":"Protective and pathogenic functions of macrophage subsets","volume":"11","author":"Murray","year":"2011","journal-title":"Nat Rev Immunol."},{"issue":"6","key":"10.1016\/j.bcp.2020.114103_b0080","first-page":"13","article-title":"The M1 and M2 paradigm of macrophage activation: time for reassessment. F1000Prime","volume":"3","author":"Martinez","year":"2014","journal-title":"Rep."},{"issue":"4","key":"10.1016\/j.bcp.2020.114103_b0085","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1093\/ibd\/izy364","article-title":"A JAK1 Selective Kinase Inhibitor and Tofacitinib Affect Macrophage Activation and Function","volume":"25","author":"De Vries","year":"2019","journal-title":"Inflamm Bowel Dis."},{"issue":"2","key":"10.1016\/j.bcp.2020.114103_b0090","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1111\/bjh.16158","article-title":"JAK1\/2 pathway inhibition suppresses M2 polarization and overcomes resistance of myeloma to lenalidomide by reducing TRIB1, MUC1, CD44, CXCL12, and CXCR4 expression","volume":"188","author":"Chen","year":"2020","journal-title":"Br J Haematol."},{"issue":"79","key":"10.1016\/j.bcp.2020.114103_b0095","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1146\/annurev-physiol-022516-034339","article-title":"Macrophage Polarization","volume":"10","author":"Murray","year":"2017","journal-title":"Annu Rev Physiol."},{"issue":"3","key":"10.1016\/j.bcp.2020.114103_b0100","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1136\/annrheumdis-2019-215894","article-title":"Global skin gene expression analysis of early diffuse cutaneous systemic sclerosis shows a prominent innate and adaptive inflammatory profile","volume":"79","author":"Skaug","year":"2020","journal-title":"Ann Rheum Dis."},{"issue":"9","key":"10.1016\/j.bcp.2020.114103_b0105","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.4049\/jimmunol.1900790","article-title":"TNF-\u03b1 and IL-10 Control CXCL13 Expression in Human Macrophages","volume":"204","author":"Bellamri","year":"2020","journal-title":"J Immunol."},{"issue":"11","key":"10.1016\/j.bcp.2020.114103_b0110","doi-asserted-by":"crossref","DOI":"10.1136\/annrheumdis-2018-214333","article-title":"M1\/M2 polarisation state of M-CSF blood-derived macrophages in systemic sclerosis","volume":"78","author":"Lescoat","year":"2019","journal-title":"Ann Rheum Dis."},{"issue":"214","key":"10.1016\/j.bcp.2020.114103_b0115","article-title":"The use of anti-inflammatory drugs in the treatment of people with severe coronavirus disease 2019 (COVID-19): The Perspectives of clinical immunologists from China","volume":"25","author":"Zhang","year":"2020","journal-title":"Clin Immunol."},{"issue":"10223","key":"10.1016\/j.bcp.2020.114103_b0120","doi-asserted-by":"crossref","first-page":"e30","DOI":"10.1016\/S0140-6736(20)30304-4","article-title":"Baricitinib as potential treatment for 2019-nCoV acute respiratory disease","volume":"395","author":"Richardson","year":"2020","journal-title":"Lancet."},{"issue":"1","key":"10.1016\/j.bcp.2020.114103_b0125","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1177\/2397198319865367","article-title":"The JAK\/STAT pathway is activated in systemic sclerosis and is effectively targeted by tofacitinib","volume":"5","author":"Wang","year":"2019","journal-title":"J. Scleroderma Related Disorders"},{"issue":"1","key":"10.1016\/j.bcp.2020.114103_b0130","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1186\/s13075-019-1963-2","article-title":"Tofacitinib facilitates the expansion of myeloid-derived suppressor cells and ameliorates interstitial lung disease in SKG mice","volume":"21","author":"Sendo","year":"2019","journal-title":"Arthritis Res Ther."},{"key":"10.1016\/j.bcp.2020.114103_b0135","doi-asserted-by":"crossref","DOI":"10.1016\/j.jid.2019.12.019","article-title":"Jak Inhibition Prevents Bleomycin-Induced Fibrosis in Mice and Is Effective in Patients with Morphea","author":"Damsky","year":"2020","journal-title":"J Invest Dermatol."},{"issue":"3","key":"10.1016\/j.bcp.2020.114103_b0140","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1111\/imcb.12217","article-title":"Efferocytosis capacities of blood monocyte-derived macrophages in systemic sclerosis","volume":"97","author":"Ballerie","year":"2019","journal-title":"Immunol Cell Biol."},{"issue":"9","key":"10.1016\/j.bcp.2020.114103_b0145","doi-asserted-by":"crossref","first-page":"5855","DOI":"10.4049\/jimmunol.0803705","article-title":"Selective oxidation of DNA topoisomerase 1 induces systemic sclerosis in the mouse","volume":"182","author":"Servettaz","year":"2009","journal-title":"J Immunol."},{"issue":"10103","key":"10.1016\/j.bcp.2020.114103_b0150","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1016\/S0140-6736(17)32594-1","article-title":"The Lancet. Systemic sclerosis: advances and prospects","volume":"390","year":"2017","journal-title":"Lancet"},{"issue":"26","key":"10.1016\/j.bcp.2020.114103_b0155","doi-asserted-by":"crossref","first-page":"2518","DOI":"10.1056\/NEJMoa1903076","article-title":"SENSCIS Trial Investigators. Nintedanib for Systemic Sclerosis-Associated Interstitial Lung Disease","volume":"380","author":"Distler","year":"2019","journal-title":"N Engl J Med"},{"issue":"10103","key":"10.1016\/j.bcp.2020.114103_b0160","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1016\/S0140-6736(17)30933-9","article-title":"Systemic sclerosis","volume":"390","author":"Denton","year":"2017","journal-title":"Lancet"},{"issue":"10038","key":"10.1016\/j.bcp.2020.114103_b0165","doi-asserted-by":"crossref","first-page":"2630","DOI":"10.1016\/S0140-6736(16)00232-4","article-title":"Safety and efficacy of subcutaneous tocilizumab in adults with systemic sclerosis (faSScinate): a phase 2, randomised, controlled trial","volume":"387","author":"Khanna","year":"2016","journal-title":"Lancet."},{"issue":"1","key":"10.1016\/j.bcp.2020.114103_b0170","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1002\/art.41055","article-title":"Abatacept in Early Diffuse Cutaneous Systemic Sclerosis: Results of a Phase II Investigator-Initiated, Multicenter, Double-Blind, Randomized","volume":"72","author":"Khanna","year":"2020","journal-title":"Placebo-Controlled Trial. Arthritis Rheumatol."},{"issue":"15","key":"10.1016\/j.bcp.2020.114103_b0175","doi-asserted-by":"crossref","first-page":"3109","DOI":"10.1182\/blood-2009-04-214957","article-title":"Preclinical characterization of the selective JAK1\/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms","volume":"115","author":"Quint\u00e1s-Cardama","year":"2010","journal-title":"Blood."},{"issue":"24","key":"10.1016\/j.bcp.2020.114103_b0180","doi-asserted-by":"crossref","first-page":"8012","DOI":"10.1021\/jm801142b","article-title":"Examining the chirality, conformation and selective kinase inhibition of 3-((3R,4R)-4-methyl-3-(methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrile (CP-690,550)","volume":"51","author":"Jiang","year":"2008","journal-title":"J Med Chem."},{"issue":"2","key":"10.1016\/j.bcp.2020.114103_b0185","doi-asserted-by":"crossref","first-page":"327","DOI":"10.3324\/haematol.2016.151126","article-title":"Primary analysis of a phase II open-label trial of INCB039110, a selective JAK1 inhibitor, in patients with myelofibrosis","volume":"102","author":"Mascarenhas","year":"2017","journal-title":"Haematologica."},{"issue":"2","key":"10.1016\/j.bcp.2020.114103_b0190","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1080\/13543776.2017.1252753","article-title":"Inhibitors of JAK-family kinases: an update on the patent literature 2013\u20132015, part 1","volume":"27","author":"Kettle","year":"2017","journal-title":"Expert Opin Ther Pat."},{"issue":"3","key":"10.1016\/j.bcp.2020.114103_b0195","doi-asserted-by":"crossref","DOI":"10.3390\/ijms19030894","article-title":"Distinct Properties of Human M-CSF and GM-CSF Monocyte-Derived Macrophages to Simulate Pathological Lung Conditions In Vitro: Application to Systemic and Inflammatory Disorders with Pulmonary Involvement","volume":"19","author":"Lescoat","year":"2018","journal-title":"Int J Mol Sci"},{"issue":"9","key":"10.1016\/j.bcp.2020.114103_b0200","doi-asserted-by":"crossref","first-page":"1896","DOI":"10.3389\/fimmu.2018.01896","article-title":"The Nrf2-Antioxidant Response Element Signaling Pathway Controls Fibrosis and Autoimmunity in Scleroderma","volume":"16","author":"Kavian","year":"2018","journal-title":"Front Immunol."},{"issue":"4","key":"10.1016\/j.bcp.2020.114103_b0205","doi-asserted-by":"crossref","first-page":"R157","DOI":"10.1186\/ar4672","article-title":"Targeting IL-6 by both passive or active immunization strategies prevents bleomycin-induced skin fibrosis","volume":"16","author":"Desallais","year":"2014","journal-title":"Arthritis Res Ther."},{"issue":"12","key":"10.1016\/j.bcp.2020.114103_b0210","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1136\/annrheumdis-2018-213257","article-title":"Association of circulating CXCL10 and CXCL11 with systemic sclerosis","volume":"77","author":"Crescioli","year":"2018","journal-title":"Ann Rheum Dis."},{"issue":"12","key":"10.1016\/j.bcp.2020.114103_b0215","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1002\/art.41020","article-title":"Progression of Interstitial Lung Disease in Systemic Sclerosis: The Importance of Pneumoproteins Krebs von den Lungen 6 and CCL18","volume":"71","author":"Volkmann","year":"2019","journal-title":"Arthritis Rheumatol."},{"key":"10.1016\/j.bcp.2020.114103_b0220","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaut.2020.102444","article-title":"CXCL4 triggers monocytes and macrophages to produce PDGF-BB, culminating in fibroblast activation: Implications for systemic sclerosis","volume":"111","author":"van der Kroef","year":"2020","journal-title":"J Autoimmun."},{"issue":"3","key":"10.1016\/j.bcp.2020.114103_b0225","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/S2213-2600(19)30480-1","article-title":"Systemic sclerosis-associated interstitial lung disease","volume":"8","author":"Perelas","year":"2020","journal-title":"Lancet Respir Med."},{"issue":"11","key":"10.1016\/j.bcp.2020.114103_b0230","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1124\/dmd.110.033787","article-title":"Metabolism, excretion, and pharmacokinetics of [14C]INCB018424, a selective Janus tyrosine kinase 1\/2 inhibitor, in humans","volume":"38","author":"Shilling","year":"2010","journal-title":"Drug Metab Dispos."},{"key":"10.1016\/j.bcp.2020.114103_b0235","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1124\/dmd.113.054940","article-title":"The pharmacokinetics, metabolism, and clearance mechanisms of tofacitinib, a janus kinase inhibitor, in humans","volume":"42","author":"Dowty","year":"2014","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.bcp.2020.114103_b0240","doi-asserted-by":"crossref","unstructured":"Gong X, Darpo B, Xue H, Punwani N, He K, Barbour AM, Epstein N, Landman R, Chen X, Yeleswaram S. Evaluation of Clinical Cardiac Safety of Itacitinib, a JAK1 Inhibitor, in Healthy Participants. Clin Pharmacol Drug Dev. (2019) [Epub ahead of print].","DOI":"10.1002\/cpdd.758"},{"key":"10.1016\/j.bcp.2020.114103_b0245","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1002\/cpdd.171","article-title":"Safety, tolerability, and pharmacokinetics of single oral doses of tofacitinib, a Janus kinase inhibitor, in healthy volunteers","volume":"4","author":"Krishnaswami","year":"2015","journal-title":"Clin Pharmacol Drug Dev"},{"issue":"4","key":"10.1016\/j.bcp.2020.114103_b0250","first-page":"559","article-title":"The Janus kinase inhibitor tofacitinib inhibits TNF-\u03b1-induced gliostatin expression in rheumatoid fibroblast-like synoviocytes","volume":"36","author":"Kawaguchi","year":"2018","journal-title":"Clin Exp Rheumatol"},{"issue":"1","key":"10.1016\/j.bcp.2020.114103_b0255","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1158\/1078-0432.CCR-18-0098","article-title":"The Novel Bromodomain and Extraterminal Domain Inhibitor INCB054329 Induces Vulnerabilities in Myeloma Cells That Inform Rational Combination Strategies","volume":"25","author":"Stubbs","year":"2019","journal-title":"Clin Cancer Res."},{"issue":"suppl 10","key":"10.1016\/j.bcp.2020.114103_b0260","article-title":"Tofacitinib in Early Diffuse Cutaneous Systemic Sclerosis\u2014 Results of Phase I\/II Investigator-Initiated, Double-Blind Randomized Placebo-Controlled Trial [abstract]","volume":"71","author":"Khanna","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.bcp.2020.114103_b0265","article-title":"In vitro pharmacological effects of peficitinib on lymphocyte activation: a potential treatment for systemic sclerosis with JAK inhibitors","volume":"25","author":"Kitanaga","year":"2019","journal-title":"Rheumatology (Oxford)."},{"issue":"2","key":"10.1016\/j.bcp.2020.114103_b0270","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1136\/annrheumdis-2017-211555","article-title":"Novel therapies for immune-mediated inflammatory diseases: What can we learn from their use in rheumatoid arthritis, spondyloarthritis, systemic lupus erythematosus, psoriasis, Crohn's disease and ulcerative colitis?","volume":"77","author":"Baker","year":"2018","journal-title":"Ann Rheum Dis."},{"issue":"1","key":"10.1016\/j.bcp.2020.114103_b0275","doi-asserted-by":"crossref","first-page":"5273","DOI":"10.1038\/s41598-018-23569-y","article-title":"Discovery of a highly selective JAK3 inhibitor for the treatment of rheumatoid arthritis","volume":"8","author":"Pei","year":"2018","journal-title":"Sci Rep."},{"issue":"6","key":"10.1016\/j.bcp.2020.114103_b0280","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1165\/rcmb.2019-0070OC","article-title":"Overexpression of TIM-3 in Macrophages Aggravates Pathogenesis of Pulmonary Fibrosis in Mice","volume":"61","author":"Wang","year":"2019","journal-title":"Am J Respir Cell Mol Biol."},{"issue":"1","key":"10.1016\/j.bcp.2020.114103_b0285","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1080\/22221751.2020.1747363","article-title":"Transcriptomic characteristics of bronchoalveolar lavage fluid and peripheral blood mononuclear cells in COVID-19 patients","volume":"9","author":"Xiong","year":"2020","journal-title":"Emerg Microbes Infect."},{"issue":"8","key":"10.1016\/j.bcp.2020.114103_b0290","doi-asserted-by":"crossref","first-page":"3018","DOI":"10.4049\/jimmunol.1502482","article-title":"Niclosamide Prevents Systemic Sclerosis in a Reactive Oxygen Species-Induced Mouse Model","volume":"197","author":"Morin","year":"2016","journal-title":"J Immunol."},{"key":"10.1016\/j.bcp.2020.114103_b0295","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.freeradbiomed.2017.03.035","article-title":"Leflunomide prevents ROS-induced systemic fibrosis in mice","volume":"108","author":"Morin","year":"2017","journal-title":"Free Radic Biol Med."},{"issue":"4","key":"10.1016\/j.bcp.2020.114103_b0300","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1136\/annrheumdis-2018-214295","article-title":"Histone modifications underlie monocyte dysregulation in patients with systemic sclerosis, underlining the treatment potential of epigenetic targeting","volume":"78","author":"van der Kroef","year":"2019","journal-title":"Ann Rheum Dis."},{"issue":"1","key":"10.1016\/j.bcp.2020.114103_b0305","doi-asserted-by":"crossref","first-page":"44","DOI":"10.3109\/01902148.2016.1141263","article-title":"RhoA\/Rho-kinase activation promotes lung fibrosis in an animal model of systemic sclerosis","volume":"42","author":"Bei","year":"2016","journal-title":"Exp Lung Res."},{"issue":"11","key":"10.1016\/j.bcp.2020.114103_b0310","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1038\/nm.4430","article-title":"Barrier-tissue macrophages: functional adaptation to environmental challenges","volume":"23","author":"Mowat","year":"2017","journal-title":"Nat Med."},{"issue":"12","key":"10.1016\/j.bcp.2020.114103_b0315","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0145342","article-title":"Novel Markers to Delineate Murine M1 and M2 Macrophages","volume":"10","author":"Jablonski","year":"2015","journal-title":"PLoS One."},{"issue":"8","key":"10.1016\/j.bcp.2020.114103_b0320","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1084\/jem.20162152","article-title":"Monocyte-derived alveolar macrophages drive lung fibrosis and persist in the lung over the life span","volume":"214","author":"Misharin","year":"2017","journal-title":"J Exp Med."},{"issue":"11","key":"10.1016\/j.bcp.2020.114103_b0325","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.1093\/rheumatology\/key214","article-title":"Synovial involvement assessed by power Doppler ultra-sonography in systemic sclerosis: results of a cross-sectional study","volume":"57","author":"Lescoat","year":"2018","journal-title":"Rheumatology (Oxford)."},{"issue":"1","key":"10.1016\/j.bcp.2020.114103_b0330","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1007\/s11926-015-0554-8","article-title":"Macrophage Involvement in Systemic Sclerosis: Do We Need More Evidence?","volume":"18","author":"Stifano","year":"2016","journal-title":"Curr. Rheumatol. Rep."},{"key":"10.1016\/j.bcp.2020.114103_b0335","doi-asserted-by":"crossref","unstructured":"Bhandari R, Ball MS, Martyanov V, Popovich D, Schaafsma E, Han S, Eltanbouly M, Orzechowski NM, Carns M, Arroyo E, Aren K, Hinchcliff M, Whitfield ML, Pioli PA. Pro fibrotic Activation of Human Macrophages in Systemic Sclerosis. Arthritis Rheumatol. (2020) [Epub ahead of print].","DOI":"10.1002\/art.41243"},{"issue":"11","key":"10.1016\/j.bcp.2020.114103_b0340","doi-asserted-by":"crossref","first-page":"219","DOI":"10.3389\/fimmu.2020.00219","article-title":"Crystalline Silica Impairs Efferocytosis Abilities of Human and Mouse Macrophages: Implication for Silica-Associated Systemic Sclerosis","volume":"18","author":"Lescoat","year":"2020","journal-title":"Front Immunol."}],"container-title":["Biochemical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295220303397?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295220303397?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T15:07:17Z","timestamp":1762096037000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006295220303397"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8]]},"references-count":68,"alternative-id":["S0006295220303397"],"URL":"https:\/\/doi.org\/10.1016\/j.bcp.2020.114103","relation":{},"ISSN":["0006-2952"],"issn-type":[{"value":"0006-2952","type":"print"}],"subject":[],"published":{"date-parts":[[2020,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Combined anti-fibrotic and anti-inflammatory properties of JAK-inhibitors on macrophages in vitro and in vivo: Perspectives for scleroderma-associated interstitial lung disease","name":"articletitle","label":"Article Title"},{"value":"Biochemical Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcp.2020.114103","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"114103"}}